NEWS
General Information
The ERA4Health Partnership is open to public institutions and organizations that provide funding at both national and regional levels from member states, associated countries, and third countries. ERA4Health is defined as a group of public funding institutions that jointly establish and implement a common funding strategy to advance health research and foster innovation in the European Research Area (ERA). While the partnership is centered around ERA, it is also open to international stakeholders.
The ERA4Health Partnership focuses on combating diseases and reducing disease burden by addressing the following challenges:
The increasing demand for a better quality of life and improved patient care.
The need to transform public health systems into more effective, efficient, equitable, accessible, and resilient ones.
The necessity of strengthening disease prevention and health promotion.
ERA4Health will support research on cardiovascular diseases (ERA-CVD), nanomedical technologies (EuroNanoMed), and the impact of nutrition on health (JPI Healthy Diet for a Healthy Life), which were previously funded under separate ERA-NET projects in Horizon 2020. This support will be provided through Joint Transnational Calls (JTCs) and is open to funding agencies/ministries supporting both basic and clinical research.
The ERA4Health Partnership will be implemented in two phases:
Phase 1: Joint calls focusing on nutrition and lifestyle-related diseases, cardiovascular diseases, and nanomedicine are being implemented. This phase covers the first two years (2023-2024) of the partnership, during which a total of four calls have been launched.
Phase 2: Additional joint calls focusing on multinational investigator-initiated clinical studies in other priority areas are expected to be launched following the decisions of the Health Programme Committee and the European Commission. This phase, which began in 2025, will include clinical trials as well as International Joint Calls (JTCs) launched under Phase 1.
ERA4Health Partnership Key Documents:
A leaflet on data sharing in clinical trial calls.
Webinars related to the ERA4Health Partnership.
Training videos for IICS (Investigator-Initiated Clinical Studies) calls.
Budget
30 Million €Call Information
The 2025 International Joint Call (InterHeart JTC2025) under the ERA4Health Partnership was opened for applications on January 7, 2025.
A total of 14 funding organizations from 12 countries are participating in the InterHeart call under the ERA4Health Partnership.
The first-stage international applications for the call titled “InterHeart: Understanding the interactions between cardiovascular diseases and comorbidities and/or their therapeutic treatments (InterHeart)” will close on March 7, 2025 (12:00 CET).
ERA4Health InterHeart 2025 Call Focus Areas
The InterHeart 2025 call aims to enhance understanding of the interactions between cardiovascular diseases and comorbidities and/or their therapeutic treatments by focusing on:
Understanding the molecular and cellular mechanisms governing interactions between the cardiovascular system and other organs/systems when at least one exhibits a pathological condition.
Developing a comprehensive approach to understanding cardiovascular disease interactions by integrating basic research, clinical applications, and digital innovations through international collaboration.
Enabling multidisciplinary scientists from different countries to collaborate across borders, benefit from complementary expertise, and use diverse patient populations and datasets.
Consortium Requirements
Each consortium must be composed of at least three institutions/organizations from three different countries participating in the partnership, with a maximum of five institutions.
A maximum of two partners from the same country can be included in the consortium.
Applicants can use the partner search platform to find consortium partners and access the ERA4Health project database for information on supported projects.
Application Process
The call follows a two-phase application process.
International applications can be submitted via the provided link.
The official international call webpage can be accessed via the provided link.
The first-stage international project applications will close on March 7, 2025 (12:00 CET).
In addition to submitting an international project application, researchers from Turkey participating in the projects must submit a national project application to TÜBİTAK via https://uidb-pbs.tubitak.gov.tr by March 11, 2025 (23:59 TRT).
Funding Mechanism
Institutions in Turkey participating in projects submitted under this call will be funded under TÜBİTAK’s 1071 International Research Support Program.
The maximum project duration is 36 months.
The TÜBİTAK funding per project, excluding Institutional Overhead Costs and Project Incentive Bonus (PTİ):
€225,000 per project
€125,000 per leading institution for higher education institutions, education and research hospitals, and public institutions/organizations
€225,000 per leading institution for private organizations
Information Days
The International Info Day presentation recording, held by the Partnership Secretariat on January 14, 2025, is available for viewing.
Key Documents
Important Notes for Applications
Consortiums must consist of a minimum of three independent institutions/organizations from at least three different countries participating in the call. The list of participating countries and institutions is available in the Call Document.
All three legal entities in the consortium must be eligible for funding and must request funding from the relevant funding organization.
The project coordinator must be eligible to receive funding from the relevant funding organization in their country.
Applicants must carefully review the international application rules and the National Application Rules Document before applying.
Contact Information
For information related to the international application process:
Şükran ALPDEMİR
sukran.alpdemir@tubitak.gov.tr
0312 298 1781
For information related to the national application process:
Azmi Serhat YILDIRIM
azmiserhat.yildirim@tubitak.gov.tr
0312 298 1823
Other Informations
Phase 1 of the Partnership will serve as a transition from diverse scientific research agenda towards a shared scientific agenda which will include the support of investigator-initiated clinical studies (IICS). During Phase 2, multinational calls for IICSs and joint calls for other priority areas will be launched.
